DAMATO, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 495
EU - Europa 410
AS - Asia 172
SA - Sud America 2
Totale 1.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 492
IE - Irlanda 165
IT - Italia 142
HK - Hong Kong 87
SE - Svezia 40
SG - Singapore 37
CN - Cina 26
GB - Regno Unito 25
RU - Federazione Russa 19
IN - India 12
UA - Ucraina 10
IR - Iran 4
CA - Canada 3
FI - Finlandia 2
FR - Francia 2
JP - Giappone 2
NL - Olanda 2
SA - Arabia Saudita 2
AT - Austria 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
DE - Germania 1
JO - Giordania 1
KR - Corea 1
Totale 1.079
Salva come PNG Salva come JPEG
Città #
Dublin 165
Altamura 80
Lawrence 80
Kent 63
Fairfield 47
Hong Kong 46
Boston 41
Princeton 41
Ashburn 35
Singapore 25
Moscow 19
San Diego 17
Wilmington 17
Shanghai 13
Seattle 12
West Jordan 12
Hillsboro 10
Rome 10
Woodbridge 10
London 8
Medford 8
Pune 8
Cambridge 7
Andover 6
Milan 6
Beijing 4
Genoa 4
Houston 4
Ann Arbor 3
Kilburn 3
Toronto 3
Boca Raton 2
Chennai 2
Chicago 2
Cincinnati 2
Dammam 2
Delhi 2
Epsom 2
Florence 2
Gualtieri 2
Legnaro 2
Nakanoki 2
Naples 2
New York 2
Perugia 2
Pescara 2
Prescot 2
Shiraz 2
Trieste 2
Trino 2
Vernon Hills 2
Aci Sant'Antonio 1
Bari 1
Bern 1
Boulder 1
Bromley 1
Carugate 1
Davis 1
Fontebuona 1
Harringay 1
Helsinki 1
Hollywood 1
Hounslow 1
Lappeenranta 1
Latina 1
Los Angeles 1
New Bedfont 1
Partinico 1
Seoul 1
Sesto Fiorentino 1
Slough 1
São Paulo 1
Vienna 1
Totale 869
Salva come PNG Salva come JPEG
Nome #
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 33
Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis 29
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 29
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology 29
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: A case series of 22 patients 26
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 26
Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma 26
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 26
Anorexia heralding the onset of neuromyelitis optica 26
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis 25
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 25
Benefit and danger from immunotherapy in myasthenia gravis 25
Eculizumab improves fatigue in refractory generalized myasthenia gravis 25
3,4-Diaminopyridine may improve myasthenia gravis with M u SK antibodies 25
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 25
Creutzfeldt-Jakob disease manifesting as stroke mimic in a 78-year-old patient: Pitfalls and tips in the diagnosis 24
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 23
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 23
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study 23
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 23
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 22
Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report 22
Conventional and emerging treatments and controversies in myasthenia gravis 22
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 22
Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders 21
In reply 21
Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations 21
Response to: “MuSK-positive myasthenia may be triggered not only by SARS-CoV-2” 20
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 20
Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors 19
Diagnostic algorithms in autoimmune encephalitis 19
Myasthenia gravis with antibodies to MuSK: An update 19
Type 1 immune response in progressive multiple sclerosis 19
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 18
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis 18
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 18
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 18
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet 18
Myasthenia gravis and related disorders 18
Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection 18
Serological and experimental studies in different forms of myasthenia gravis 18
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 18
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 18
Heterogeneity in myasthenia gravis: considerations for disease management 18
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 17
The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders 17
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 16
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 16
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4 16
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 15
When myasthenia gravis is not all 15
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 15
Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders 12
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 10
Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab 8
Epidemiology of seropositive myasthenia gravis in Sardinia: A population‐based study in the district of Sassari 5
Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome 4
Totale 1.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 0 0 0 0 0 0 104 24 1 14 75
2022/2023491 68 161 16 17 0 89 89 3 19 10 13 6
2023/2024402 11 17 68 17 33 40 15 63 9 35 72 22
2024/202536 36 0 0 0 0 0 0 0 0 0 0 0
Totale 1.147